Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Fukasawa T, Yoshizaki A, Ebata S, Nakamura K, Saigusa R, Miura S, Yamashita T, Hirabayashi M, Ichimura Y, Taniguchi T, Asano Y, Shimizu H, Kazoe Y, Mawatari K, Kitamori T, Sato S.
Fukasawa T, et al.
Arthritis Rheumatol. 2017 Sep;69(9):1879-1890. doi: 10.1002/art.40164. Epub 2017 Aug 1.
Arthritis Rheumatol. 2017.
PMID: 28556548